Last update 01 Nov 2024

LILRB2 x LILRB3 x LILRB1

Last update 01 Nov 2024

Basic Info

Related Targets

LILRB2LILRB3LILRB1

Drugs associated with LILRB2 x LILRB3 x LILRB1

LITCHI-7

Target

LILRB1 x LILRB2 x LILRB3

Mechanism

LILRB1 inhibitors [+2]

Active Org.

AbbVie Biotherapeutics, Inc.

Originator Org.

AbbVie Biotherapeutics, Inc.

Active Indication

Neoplasms

Inactive Indication-

Drug Highest PhasePreclinical

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

100 Clinical Results associated with LILRB2 x LILRB3 x LILRB1

100 Translational Medicine associated with LILRB2 x LILRB3 x LILRB1

0 Patents (Medical) associated with LILRB2 x LILRB3 x LILRB1

Literatures (Medical) associated with LILRB2 x LILRB3 x LILRB1

01 Dec 2022·World Journal of Surgical OncologyQ3 · MEDICINE

Analysis of the expression and prognosis for leukocyte immunoglobulin-like receptor subfamily B in human liver cancer

Q3 · MEDICINE

ArticleOA

Author: Fan, Jing ; Song, Fangnan ; Wang, Lili ; Zhang, Jiakang ; Yi, Yongxiang ; Chen, Miao ; Yin, Dandan ; Li, Jiayan ; Gu, Aidong

AbstractBackgroundLeukocyte immunoglobulin-like receptor subfamily B (LILRB), including 5 subtypes, is a group of inhibitory receptors in the immune system. The LILRB family is known to be involved in the tumor progression of various cancer types, especially liver cancer. However, the expression patterns and prognostic values of LILRB family members in liver cancer tissues remain unclear.MethodsWe used the Oncomine database, GEPIA database, Kaplan–Meier Plotter, Timer, and TISIDB to assess the expression and prognostic value of the LILRB family in liver cancer patients. We also verified the expression of the LILRB family in tumor tissues and tumor-free liver tissues at the protein level by using immunohistochemistry. The STRING website was used to explore the interaction between the LILRB family and their related genes. The DAVID database was used to perform the gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses. Flow cytometry was used to assess the infiltrated NK cells in liver cancer tissues.ResultsOur study revealed that the mRNA expression of LILRB1, LILRB2, LILRB3, and LILRB5 was downregulated, while compared with normal tissues, the mRNA expression of LILRB4 was upregulated in liver cancer tissues. Survival analysis revealed that LILRB2 and LILRB5 mRNA expression levels were significantly positively associated with overall survival (OS) and disease-free survival (DSS) and that the mRNA expression of all LILRB family members was significantly positively correlated with recurrence-free survival (RFS) and progression-free survival (PFS). Next, we further found that the mRNA expression of all LILRB family members was significantly associated with the infiltration of B cells, CD8+ T cells, CD4+ T cells, macrophages, neutrophils, and dendritic cells in liver cancer. Finally, GO and KEGG analyses found that the LILRB family and its related genes were involved in antigen processing and presentation and natural killer cell-mediated cytotoxicity pathways.ConclusionsOur study suggested that LILRB family expression was associated with the prognosis of liver cancer patients and infiltrated immune cells. The LILRB family might be involved in antigen processing and presentation and natural killer cell-mediated cytotoxicity pathways.

01 Aug 2021·Molecular ImmunologyQ3 · MEDICINE

Expression of leukocyte immunoglobulin-like receptor subfamily B expression on immune cells in hepatocellular carcinoma

Q3 · MEDICINE

Article

Author: Fan, Jing ; Duan, Jie ; Gu, Aidong ; Han, Jianbo ; Song, Fangnan ; Zhang, Yufeng ; Yi, Yongxiang ; Yin, Dandan ; Li, Jiayan ; Wang, Lili

BACKGROUNDLeukocyte immunoglobulin-like receptor subfamily B (LILRB) is a group of inhibitory receptors involved in innate immune mainly expressed on lymphoid and myelomonocytic cells. LILRB is proposed to serve as immune checkpoint like PD-1 and CTLA-4 for tumor treatment. We recently reported that the expression of LILRB2 in CD1c⁺ mDC from tumor tissue might suppress immune for HCC patients. However, the expression of all the LILRB family on other immune cells in peripheral blood and tumor microenvironment of HCC patients has not been systematically studied.METHODSThe expression of LILRB family (LILRB1, LILRB2, LILRB3, LILRB4 and LILRB5) on immune cells, including granulocytes, NK cells, NKT cells, monocyte subsets, TAMs, B cells, γδ T cells, CD4⁺ T cells, CD8⁺ T cells and MDSC subsets, was analyzed by ﬂow cytometry in the peripheral blood of 20 HCC patients and 20 healthy donors as well as in the tumor and tumor free tissues of 10 HCC patients.RESULTSLILRB1, LILRB2 and LILRB3 in granulocytes from peripheral blood were expressed increased in HCC patients compared with healthy donors. The expression of LILRB5 in NK cells and NKT cells from HCC blood were higher compared with healthy donors` blood. CD14⁺CD16⁺ monocyte subsets in blood of HCC patients expressed increased LILRB1 and LILRB4 than that in healthy donors. CD14⁺CD16^- monocyte subsets in blood of HCC patients expressed increased LILRB3 than that in healthy donors. Compared to corresponding TFL, LILRB3, LILRB4 and LILRB5 were expressed enhanced in TAMs from HCC tumors. LILRB1 expressed on the B cells both in the blood and tumor had significantly increased compared with healthy donors or corresponding TFL. Different from peripheral blood, in the HCC microenvironment, CD4⁺ T cells expressed lower LILRB2, LILRB3 and LILRB4 than that from TFL and CD8⁺ T cells expressed decreased LILRB2. And γδ T cells expressed LILRB1 in HCC blood and microenvironment. Surprisingly, the percentage of LILRB1 expressed on MDSC from HCC peripheral blood and tumors was lower than that from healthy donors and corresponding TFL.CONCLUSIONSThis is the first systemically examination of the LILRB family expression on a variety of immune cells from both peripheral blood and microenvironment in HCC patients. The specific increasing expression of LILRB on immune cells may regulate innate and adaptive immune and impact on HCC progression. Our findings justify further investigation of LILRB function in HCC.

01 Oct 2004·European Journal of ImmunologyQ3 · MEDICINE

A gene signature of inhibitory MHC receptors identifies a BDCA3⁺ subset of IL‐10‐induced dendritic cells with reduced allostimulatory capacity in vitro

Q3 · MEDICINE

Article

Author: Patraporn Metharom ; Johannes Bohlender ; Sergij Goerdt ; Florian W Velten ; Karine Duperrier

AbstractDendritic cells (DC) are crucial gatekeepers in regulating immunity. Whereas mature immunostimulatory myeloid DC (DCims) potently promote immune responses, IL‐10‐induced myeloid DC (DC‐IL‐10) counteract T cell activation. To elucidate the molecular repertoire by which DC‐IL‐10 secure reduced T cell activation, comparative gene expression profiling was done using Affymetrix U133A microarrays. Among the genes overexpressed in DC‐IL‐10, eight immunoreceptor tyrosine‐based inhibitory motif (ITIM)‐containing inhibitory molecules (ILT2, ILT3, ILT4, ILT5, DCIR, PILRA, FcγRIIB, SLAM) were found. Phenotypic analysis of DC‐IL‐10 defined an ILThigh DC subset further characterized by expression of CD14, TLR2, DC‐SIGN, and CD123 and the lack of lymphocyte, monocyte/macrophage, and plasmacytoid DC markers such as CD3, CD8, and CD68. A unique feature of the ILThigh DC subset was expression of the novel DC marker BDCA3, which was not detected on monocytes, immature DC, DCims, or ILTlow DC‐IL‐10. While the allogeneic T cell proliferation induced by the entire DC‐IL‐10 population was approximately 30% of that stimulated by DCims, allogeneic MLR responses driven by the ILThigh DC subset were reduced to 8% of the allostimulatory capacity of DCims, although secretion of the inhibitory cytokine IL‐10 and other Th1/Th2‐associated cytokines was similar in these cells.

Analysis

Perform a panoramic analysis of this field.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis